AbbVie reported a win in a Phase 3 multiple myeloma study for etentamig, a dual-acting bispecific antibody designed to engage T cells and target tumor cells. In the trial, etentamig met the main goal by improving survival without disease progression compared with standard regimens for patients who had progressed on multiple prior lines. AbbVie also highlighted a safety profile with low rates of two serious immune responses commonly associated with bispecific antibodies, a point that could matter for treatment settings where intensive post-infusion monitoring is a barrier. The study enrolled 421 patients and included an interim checkpoint that prompted unblinding, leaving 393 evaluable participants at an average follow-up of 11 months. The development tightens competitive pressure in the fast-moving bispecific and CAR-T-adjacent blood cancer landscape, where durability and tolerability increasingly drive adoption. AbbVie’s readout also positions etentamig as a contender for broader outpatient use if the safety signal holds as longer follow-up matures.